Biotest AG (DE:BIO)
HAMBURG:BIO
Top Page
Biotest
(Hamburg:BIO)
Select Model
Select Model
Rating:51Neutral
Price Target:
€33.00
▼(-8.84% Downside)
Action:ReiteratedDate:10/23/25
Biotest's overall stock score is primarily influenced by its financial performance, which is stable but faces profitability challenges. The technical analysis indicates a bearish trend, and the valuation is concerning with a negative P/E ratio. The high dividend yield is a positive aspect but may not be sustainable.
Positive Factors
Secured plasma supply (vertical integration)
Owning plasma collection centers secures raw material supply for immunoglobulins and albumin, reducing reliance on third parties. This durable vertical integration supports production continuity, price negotiation power with buyers, and lowers supply disruption risk over the medium term.
Negative Factors
Inconsistent revenue trends
Fundamentals show a pronounced negative revenue-growth metric, despite a reported 6.08% year-over-year rise in 2023–24. This mismatch signals inconsistent top-line performance across reporting periods, making capacity planning, investment sizing and long-term forecasting more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Secured plasma supply (vertical integration)
Owning plasma collection centers secures raw material supply for immunoglobulins and albumin, reducing reliance on third parties. This durable vertical integration supports production continuity, price negotiation power with buyers, and lowers supply disruption risk over the medium term.
Read all positive factors
Biotest (BIO) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.45B
Dividend YieldN/A
Average Volume (3M)73.00
Price to Earnings (P/E)―
Beta (1Y)-0.02
Revenue Growth-18.82%
EPS Growth-113.85%
CountryDE
Employees2,495
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,785,727
10 Day Avg. Volume62
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotest Business Overview & Revenue Model
Company Description
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunolog...
How the Company Makes Money
Biotest generates revenue primarily through the sale of its plasma-derived products, including immunoglobulins, clotting factors, and albumin. The company operates plasma collection centers to source the raw material necessary for its products, wh...
Biotest Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 726.20M | 684.60M | 516.10M | 515.60M | 484.20M |
| Gross Profit | 223.80M | 280.30M | 124.90M | 80.70M | 130.10M |
| EBITDA | 120.40M | 179.00M | 28.30M | -17.70M | 16.00M |
| Net Income | 26.40M | 127.00M | -31.60M | -63.30M | -31.40M |
Balance Sheet | |||||
| Total Assets | 1.43B | 1.41B | 1.20B | 1.10B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 119.50M | 118.50M | 136.60M | 117.50M | 89.20M |
| Total Debt | 597.20M | 689.80M | 574.30M | 496.30M | 469.10M |
| Total Liabilities | 903.30M | 912.00M | 831.90M | 723.80M | 689.70M |
| Stockholders Equity | 530.70M | 498.90M | 371.10M | 380.40M | 441.60M |
Cash Flow | |||||
| Free Cash Flow | 32.20M | -36.10M | -69.80M | 15.70M | -43.70M |
| Operating Cash Flow | 60.90M | -2.70M | -40.50M | 33.90M | -16.70M |
| Investing Cash Flow | -25.70M | 1.30M | -37.00M | -23.40M | -14.60M |
| Financing Cash Flow | -35.40M | -6.80M | 89.60M | 22.60M | 42.00M |
Biotest Technical Analysis
Positive
36.20
Price Trends
37.06
Positive
36.82
Positive
38.35
Positive
Market Momentum
1.11
Negative
70.00
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Positive. The current price of 36.2 is below the 20-day moving average (MA) of 37.66, below the 50-day MA of 37.06, and below the 200-day MA of 38.35, indicating a bullish trend. The MACD of 1.11 indicates Negative momentum. The RSI at 70.00 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BIO.
Biotest Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €315.64M | -2.28 | -39.02% | ― | -14.84% | -338.52% | |
51 Neutral | €1.45B | -66.55 | 4.98% | ― | -18.82% | -113.85% | |
46 Neutral | €52.43M | -4.72 | -337.77% | ― | -4.90% | -69.80% | |
42 Neutral | €130.53M | -3.18 | -391.55% | ― | -64.15% | -39.31% |
* General Sector Average
DE:BIO
Biotest
41.20
-1.40
-3.29%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.40
0.05
2.13%
DE:CNW
co.don AG
0.01
0.00
0.00%
DE:MDG1
Medigene
0.04
-0.21
-85.19%
DE:HPHA
Heidelberg Pharma AG
2.79
0.16
6.08%
DE:FYB
Formycon AG
17.86
-3.99
-18.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.